KRAS and NRAS mutated colorectal cancers (CRC) are known to be resistant to epithelial growth factor receptor (EGFR)-targeted therapy [36], suggesting that this type of treatment may also be ineffective in PMP. Here, KRAS is linked to colorectal cancer.